Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, announced that it has dosed the first patien...
GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, announced its participation as a Platinum Spo...
Rezubio announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA a...
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certifica...
HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Soci...
Perceptra Co., Ltd., a Thai startup developing artificial intelligence technology for medical image analysis, has officially announced its entry into ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Au...
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, announced that the New Dr...
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML Innovent Biologics, Inc. (01801.HK) and ...
CellFiber Co., Ltd. (“CellFiber”), a Tokyo-based biotechnology company built on its proprietary CellFiber® cell encapsulation platform, a...
Nanjing Leads Biolabs Co., Ltd. announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibo...
Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
© 2026 Biopharma Boardroom. All Rights Reserved.
